Profile

Pan Hongming, Male, was born in 1963. He is a B.S. and M.D. Supervisor of Zhejiang University, an attending Physician and director of Medical Oncology of Sir Run Run Shaw Hospital; Dr. Pan has enough experiences and excellent technique in treating common cancer with chemotherapy, immunotherapy, molecular targeted therapy and radiofrequency ablation, etc.
Dr Pan is an active member of American Society of Clinical Oncology (ASCO), Chief Committee of Chinese Society of Clinical Oncology (CSCO),Committee of Cancer Chemotherapy of Chinese Anti-cancer Society, Vice-director Committee of Cancer Chemotherapy of Zhejiang Anti-cancer Society. He has lectured extensively and published more than 60 cancer –related articles in Chinese or English journals, also edited chiefly three books in Chinese. He has joined more than 30 international clinical trial about new anticancer drugs approved by FDA.

Permanent Address :Medical Oncology of Sir Run Run Shaw Hospital, Zhejiang University, 3 Qingchun Road East,Hangzhou,310016, P. R. China
E-mail:panhongming@tom.com, Fax:86-571-86436673
Tel:86-571-86006922(office)

Education & Working experiences:
2008.1-2 Visiting Physician of Medical Oncology, Mayo Clinic, MST, USA.
1998-present Director & Attending physician of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University
1997 Fellowship in Medical Oncology , Loma Linda University, CA, USA
1995-1997 Fellow of Medical Oncology, Sir Run Run Shaw Hospital,
Zhejiang University
1990-1995 :M.D. training in Oncology, Zhejiang Medical University
1981-1987 :B.S. training in Medicine, Zhejiang Medical University

Major Publications(8 papers in English and 3 books in Chinese):
1.Pan Hongming(co-author).Resource utilization by histology for pemetrexed as maintenance therapy in advanced non-small cell lung cancer: Results from the randomized, double-blind phase III trial. ESMO 2008.
2.Pan Hongming, Zaiyun Zhang, et al. Efficacy and tolerability of oxycodone HCl
controlled-release tablets on moderate to severe cancer pain. Clin Drug Invest., 27(4):259-267, 2007.
3.Pan Hongming, Xu Nong. Technique of Drug Therapy in Medical Oncology. 1st Ed, 2007, Chinese Science and Technology Publications.
4.Pan Hongming, et al. A phase Ⅱstudy of oxaliplatin with ELF regimen in patients with advanced gastric cancer. June 5-8, 2004, 40th annual meeting. ASCO
5.Xu Ligong, Pan hongming , et al. Capecitabine combined with trastuzumab as first-line therapy in patients with HER2-overexpressing metastatic breast cancer. Annals of oncology . 2004,15,Suppl 3: 38.
6. Ye Meng, Pan Hongming, Wang Haiyun, et al. Catheter associated Complications
of Intraperitoneal Chemotherapy in Advanced Gastric Cancer. World J Gastroenterol , 2003.
7.Pan hongming, et al. Oxaliplatin in combination with fluorouracil and leucovorin as the treatment of advanced gastro-intestinal carcinoma. Program/proceedings ASCO, Thirty-eighth annual meeting, May18-21,2002,Orlando,FL.
8. Pan Hongming, et al. Ultra-Cut Biopsy Guided by Ultrasonography for Liver Lesions: Experience of 392 Clinical Cases Journal of Zhejiang University SCIENCE Jul,2002
9. Pan Hongming, Xu Nong,Geng Baoqin. Diagnostic and Treatment Strategy in Medical Oncology. 1st Ed, 2002, Shanghai Science and Technology Publications.
10. Pan Hongming, Geng Baoqin. Prevention and treatment on the Side Effects of Cancer Chemotherapy. 1st Ed, 2001, Shanghai Science and Technology Publications.
11.Pan Hongming, et al. The chemopreventive effect of green tea and tea polyphenols on dimethlhydrazine-induced colorectal cancer in ICR mice. Program/proceedings ASCO, Thirty-fifth annual meeting, May15-18, 1999, Atlanta, GA.